LIABLE Act
- Bill Number
- H.R. 1432
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-02-18: Referred to the House Committee on the Judiciary.
- Last Updated
- 2025-07-09T14:20:58Z
AI-Generated Summary
Purpose of the Legislation
The LIABLE Act (H.R. 1432) aims to eliminate federal legal protections that shield manufacturers of COVID-19 vaccines from lawsuits or liability for injuries or losses caused by the vaccines. It seeks to empower individuals harmed by these vaccines to pursue civil claims directly against manufacturers, while preserving access to existing government compensation programs.
Key Provisions
- Prohibition on Immunity: No federal law can grant immunity from lawsuits or limit liability for COVID-19 vaccine manufacturers regarding claims for losses (e.g., injuries, damages) stemming from the vaccine's administration or use.
- Preservation of Compensation Programs: Individuals can still seek no-fault compensation through the Countermeasures Injury Compensation Program (CICP) or the National Vaccine Injury Compensation Program (VICP), which are government-funded systems for vaccine-related injuries.
- Right to Sue Regardless of Compensation: Filing for or receiving benefits from CICP or VICP does not prevent someone from filing a separate civil lawsuit against the manufacturer.
- Definition of COVID-19 Vaccine: Refers to any vaccine approved or authorized by the Food and Drug Administration (FDA) to prevent, reduce, or limit harm from COVID-19 or the transmission of SARS-CoV-2 (the virus causing COVID-19) or its variants.
- Retroactive Application: The law would apply to vaccine administrations or uses before, on, or after its enactment date, potentially reopening past cases.
Significant Changes to Existing Law
- Overrides Specific Protections: Directly nullifies immunity provisions in key federal laws, such as Section 319F-3 of the Public Health Service Act (the PREP Act, which provides liability shields during public health emergencies) and certain sections of the National Childhood Vaccine Injury Act (which limits manufacturer liability for routine vaccines).
- Expands Legal Recourse: Unlike current law, where injured parties are often limited to government compensation programs without the option to sue manufacturers, this bill allows direct civil actions while keeping those programs intact.
- Targets COVID-19 Vaccines Only: Changes apply exclusively to COVID-19 vaccines, leaving liability rules for other vaccines unchanged.
Potential Impacts
- On Citizens: Injured individuals gain stronger pathways to seek damages through lawsuits, potentially leading to higher compensation but also requiring them to prove fault in court, which can be time-consuming and costly.
- On Government Agencies: Agencies like the Department of Health and Human Services (HHS) and FDA may face increased administrative burdens from more litigation, and future public health emergency responses could be complicated by reduced incentives for manufacturers to develop countermeasures quickly.
- On Manufacturers and Businesses: Vaccine makers (e.g., pharmaceutical companies) could face significant financial risks from lawsuits, possibly increasing costs passed on to consumers or governments, and deterring rapid vaccine development in future pandemics.
- On International Relations: Minimal direct impact, though it could affect U.S. collaborations with global vaccine producers or influence how other countries structure liability for international health initiatives.
Main Stakeholders Affected
- Injured Individuals and Families: Primary beneficiaries, as they can pursue legal claims against manufacturers for vaccine-related harms.
- Vaccine Manufacturers: Face removed protections, increasing exposure to lawsuits and potential financial liabilities.
- Government Agencies (e.g., HHS, FDA, DOJ): Must administer unchanged compensation programs while defending against or overseeing related litigation.
- Healthcare Providers and Insurers: May see indirect effects, such as changes in vaccine distribution practices or rising insurance premiums due to broader liability concerns.
- Taxpayers: Could experience shifts in costs, as government compensation programs remain but private lawsuits might reduce reliance on public funds.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Could lead to a surge in litigation challenging vaccine safety and efficacy, potentially setting precedents for product liability in public health contexts. The retroactive clause might invite constitutional challenges over due process (fair notice of liability) or ex post facto laws (applying new rules to past actions), though it targets civil liability rather than criminal penalties.
- Constitutional Implications: Raises questions about Congress's authority to override executive branch emergency powers under the Public Health Service Act, possibly testing separation of powers between legislative and executive branches.
- Political Implications: Highlights tensions between public health protections and individual rights, likely sparking debates on vaccine policy, emergency preparedness, and corporate accountability in Congress and the courts. As an introduced bill in the 119th Congress, its passage would depend on committee review and broader political support.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (11)
Rep. Massie, Thomas [R-KY-4], Rep. Brecheen, Josh [R-OK-2], Rep. Cloud, Michael [R-TX-27], Rep. Higgins, Clay [R-LA-3], Rep. Crane, Elijah [R-AZ-2], Rep. Gosar, Paul A. [R-AZ-9], Rep. Perry, Scott [R-PA-10], Rep. Davidson, Warren [R-OH-8], Rep. Norman, Ralph [R-SC-5], Rep. Harris, Andy [R-MD-1], Rep. Fulcher, Russ [R-ID-1]
Recent Actions
- 2025-02-18: Referred to the House Committee on the Judiciary.
- 2025-02-18: Introduced in House
- 2025-02-18: Introduced in House
Bill Versions
- Let Injured Americans Be Legally Empowered Act — issued 2025-02-18 — PDF (3 pages)